Beijing Tongren Hospital recently signed data transaction agreements with Hengrui Pharmaceuticals and Bayer, which the hospital claims marks the world's first compliant transaction of a full-dimensional ophthalmic follow-up dataset.

The data will support the research and development of new ophthalmic drugs, real-world studies, artificial intelligence model development, and other applications, with an aim to benefit eye disease patients eventually, according to the hospital.

Yuan Jin, president of the hospital, said that the transaction lies in the hospital's multi-dimensional full-structure quantitative ophthalmic database built upon a population of 100,000 people. The database includes full-scale ocular follow-up datasets covering prevalent eye disorders such as keratopathy, dry eye disease, myopia, glaucoma, cataracts, and diabetic retinopathy.

It integrates demographic profiles, clinical diagnoses, treatment regimens, long-term follow-up records, and ophthalmic imaging data to provide real-world evidence for drug research, post-marketing evaluation, medical insurance access, and other scenarios, according to Yuan.

Relying on two authoritative compliance platforms — the National AI Application Pilot Base (Medical Sector) and the Beijing International Big Data Exchange — the hospital said all sensitive personal information has been anonymized.